Efficacy and tolerability of a 5% lidocaine medicated plaster in adult patients with localized neuropathic pain: a retrospective analysis of open-label real-world data provided by the German Pain e-Registry (EVERS)

Study identification

• PURI:
  https://redirect.ema.europa.eu/resource/32827
• EU PAS number:
  EUPAS32826
• Study ID:
  32827
• Official title and acronym:
  Efficacy and tolerability of a 5% lidocaine medicated plaster in adult patients with localized neuropathic pain: a retrospective analysis of open-label real-world data provided by the German Pain e-Registry (EVERS)
• DARWIN EU® study:
  No
• Study countries:
  Germany
• Study description:
  Retrospective analysis of anonymized real-world data provided by the German Paine-Registry on the effectiveness, safety and tolerability of a topical treatment with 5% lidocaine medicated plaster vs. recommended oral/systemic drugs in patients with peripheral localized neuropathic pain who showed an inadequate response to at least one recommended systemic/oral first line drug under conditions of routine clinical practice.
• Study status:
  Ongoing

Research institutions and networks

Institutions

O.Meany-MDPM

Study timelines

Date when funding contract was signed

Planned: 21/11/2019

Actual: 25/11/2019

Study start date

Planned: 17/12/2019

Actual: 17/12/2019

Data analysis start date

Planned: 01/01/2020

Date of final study report

Planned: 31/01/2020

Sources of funding

Pharmaceutical company and other private sector 

Non-for-profit organisation (e.g. charity)

More details on funding

Grünenthal, Institute of Neurological Sciences

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable